MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, DOMH had $29,926K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$29,926K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Stock-based compensation employ...
    • Dominari Financial
    • Stock-based compensation adviso...
    • Others
Negative Cash Flow Breakdown
    • Unrealized (gain) loss on market...
    • Legacy AIkido Pharma
    • Non-cash underwriting revenues
    • Others

Cash Flow
2025-12-31
Dominari Financial
23,337
Legacy AIkido Pharma
-36,491
Net income (/loss) before income taxes
-13,154
Provision for income taxes
7,318
Net loss
-20,472
Amortization of right-of-use assets
223
Depreciation
105
Non-cash underwriting revenues
27,327
Non-cash commission expense
20,341
Stock-based compensation employees
33,978
Stock-based compensation advisors
21,029
Realized gain on marketable securities
345
Unrealized (gain) loss on marketable securities
42,254
Unrealized (gain) loss on securities owned
1,593
Realized and unrealized (gain) loss on note receivable
221
Prepaid expenses and other assets
451
Receivable from clearing brokers
-13,284
Accounts payable and accrued expenses
-309
Accrued compensation and commissions
15,697
Contract liabilities
3,404
Right of use asset and liability, net
-198
Income taxes payable
7,318
Securities owned
-441
Other liabilities
91
Notes receivable, at fair value - net interest accrued
21
Net cash provided by (used in) operating activities
22,720
Purchase of marketable securities
18,034
Sale of marketable securities
17,857
Collection of principal on note receivable
1,144
Redemption of long-term investments
538
Collection of loans to employees
383
Net cash provided by investing activities
1,888
Cash paid for dividends
11,898
Distributions to non-controlling interest
1,963
Cash from issuance common stock, net of offering cost
13,551
Cash from issuance common stock for exercised warrants
5,628
Net cash provided by financing activities
5,318
Net increase in cash and cash equivalents
29,926
Cash and cash equivalents, beginning of period
4,079
Cash and cash equivalents, end of period
34,005
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Stock-based compensation employees$33,978K Cash from issuancecommon stock, net of...$13,551K Sale of marketablesecurities$17,857K Stock-based compensation advisors$21,029K Non-cash commissionexpense$20,341K Accrued compensationand commissions$15,697K Receivable from clearingbrokers-$13,284K Income taxes payable$7,318K Contract liabilities$3,404K Securities owned-$441K Amortization of right-of-useassets$223K Depreciation$105K Other liabilities$91K Cash from issuancecommon stock for...$5,628K Collection of principal onnote receivable$1,144K Redemption of long-terminvestments$538K Collection of loans toemployees$383K Net cash provided by(used in) operating...$22,720K Net cash provided byfinancing activities$5,318K Net cash provided byinvesting activities$1,888K Canceled cashflow$93,191K Canceled cashflow$13,861K Canceled cashflow$18,034K Net increase in cashand cash...$29,926K Unrealized (gain) loss onmarketable securities$42,254K Non-cash underwritingrevenues$27,327K Net loss-$20,472K Unrealized (gain) loss onsecurities owned$1,593K Prepaid expenses andother assets$451K Realized gain onmarketable securities$345K Accounts payable andaccrued expenses-$309K Realized and unrealized(gain) loss on note...$221K Right of use asset andliability, net-$198K Notes receivable, atfair value - net...$21K Cash paid fordividends$11,898K Distributions tonon-controlling interest$1,963K Purchase of marketablesecurities$18,034K Dominari Financial$23,337K Net income (/loss)before income taxes-$13,154K Provision for income taxes$7,318K Canceled cashflow$23,337K Legacy AIkido Pharma-$36,491K

Dominari Holdings Inc. (DOMH)

Dominari Holdings Inc. (DOMH)